Diligence memo · auto-generated · as of July 2, 2026
ImmuneBridge Inc.
ImmuneBridge Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
ImmuneBridge Inc. operates in Biotechnology, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ImmuneBridge Inc. has raised $16M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2022-12-27.
Most recent recorded round closed around 2025-03-24.
Valuation (modeled)modeled
Provath models ImmuneBridge Inc. at approximately $21M (range $6.1M–$38M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.33× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era. Within the normal band (133% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 27 months.
Last raise 15 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 64% of Biotechnology peers (4293 compared).
Modeled value ranks above 29% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.